版本:
中国

BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma

March 14 Merck & Co Inc

* FDA approves Merck's Keytruda® (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment, or who have relapsed after three or more prior lines of therapy

* Merck & Co - FDA has approved keytruda for treatment of adult and pediatric patients with refractory classical hodgkin lymphoma Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐